Complications of prostate biopsy

Expert Review of Anticancer Therapy

Volumn 13, Issue 7, 2013, Pages 829-837

  Anastasiadis, Anastasios ^a   Zapała, Łukasz ^b   Cordeiro, Ernesto ^a   Antoniewicz, Artur ^b   Dimitriadis, Georgios ^c   De Reijke, Theo ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Multidisciplinary Hospital Warsaw Miedzylesie   (Poland)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

genitourinary infections; hematuria; prostate biopsy; prostate biopsy complications; prostate cancer

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIBIOTIC AGENT; CIPROFLOXACIN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

ANTIBIOTIC THERAPY; ANTICOAGULATION; BLADDER CATHETERIZATION; BLOOD VESSEL CLIP; DIGITAL RECTAL EXAMINATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; EPIDIDYMITIS; FAINTNESS; HEMATURIA; HEMOSPERMIA; HOSPITALIZATION; HUMAN; INTESTINAL BLEEDING; LOCAL ANESTHESIA; NERVE BLOCK; PATIENT SAFETY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE INFECTION; POSTOPERATIVE PAIN; PREMEDICATION; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATITIS; QUALITY OF LIFE; RECTUM HEMORRHAGE; RESIDUAL URINE; REVIEW; SEPSIS; SEPTICEMIA; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT INDICATION; URINARY TRACT INFECTION; URINE RETENTION;

EID: 84880793898     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2013.811056     Document Type: Review

References (68)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA. Cancer J. Clin. 62(1), 10-29 (2012
2. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer 46(4), 765-781 (2010
3. Epstein JI, Walsh PC, Sauvageot J, Carter HB. Use of repeat sextant and transition zone biopsies for assessing extent of prostate cancer. J. Urol. 158(5), 1886-1890 (1997
4. Fleshner NE, OSullivan M, Fair WR. Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate. J. Urol. 158(2), 505-508; discussion 508 (1997
5. Rabbani F, Stroumbakis N, Kava BR, Cookson MS, Fair WR. Incidence and clinical significance of false-negative sextant prostate biopsies. J. Urol. 159(4), 1247-1250 (1998
6. Antoniewicz AA, ZapaŁa Ł, Bor̈ka A, De Reijke T. Biopsy of the prostate -The urge to search for a new standard. CEJU 63(4), 166-175 (2010
7. Challacombe B, Dasgupta P, Patel U, Amoroso P, Kirby R. Recognizing and managing the complications of prostate biopsy. BJU Int. 108(8), 1233-1234 (2011
8. Hasegawa T, Shimomura T, Yamada H et al. Fatal septic shock caused by transrectal needle biopsy of the prostate; a case report. Kansenshogaku Zasshi. 76(10), 893-897 (2002
9. Carlsson SV, Holmberg E, Moss SM et al. No excess mortality after prostate biopsy: Results from the European Randomized Study of Screening for Prostate Cancer. BJU Int. 107(12), 1912-1917 (2011
10. Ecke TH, Gunia S, Bartel P, Hallmann S, Koch S, Ruttloff J. Complications and risk factors of transrectal ultrasound guided needle biopsies of the prostate evaluated by questionnaire. Urol. Oncol. 26(5), 474-478 (2008
11. Raaijmakers R, Kirkels WJ, Roobol MJ, Wildhagen MF, Schrder FH. Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology 60(5), 826-830 (2002
12. Rodrüez LV, Terris MK. Risks and complications of transrectal ultrasound guided prostate needle biopsy: A prospective study and review of the literature. J. Urol. 160(6 Pt 1), 2115-2120 (1998
13. Silletti JP, Gordon GJ, Bueno R, Jaklitsch M, Loughlin KR. Prostate biopsy: Past, present, and future. Urology 69(3), 413-416 (2007
14. Weber B, Saliken J, Jadavji T, Gray RR, Moore R. A near-fatal case of sepsis with an antibiotic-resistant organism complicating a routine transrectal prostate biopsy in a health care worker. Can. Urol. Assoc. J. 2(5), 543-545 (2008
15. Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM. Complications after prostate biopsy: Data from SEER-Medicare. J. Urol. 186(5), 1830-1834 (2011
16. Merrick GS, Gutman S, Andreini H et al. Prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy. Eur. Urol. 52(3), 715-723 (2007
17. Klein T, Palisaar RJ, Holz A, Brock M, Noldus J, Hinkel A. The impact of prostate biopsy and periprostatic nerve block on erectile and voiding function: A prospective study. J. Urol. 184(4), 1447-1452 (2010
18. Wu MW, Sevilla EM, Raman L, Consigliere D, Siow WY, Tiong HY. Incidence of complications after transrectal ultrasonography-guided biopsy of the prostate in a local tertiary institution. Singapore Med. J. 52(10), 752-757 (2011
19. Djavan B, Waldert M, Zlotta A et al. Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: Results of a prospective European prostate cancer detection study. J. Urol. 166(3), 856-860 (2001
20. Kakehi Y, Naito S; Japanese Urological Association. Complication rates of ultrasound-guided prostate biopsy: A nation-wide survey in Japan. Int. J. Urol. 15(4), 319-321 (2008
21. Moreno Alarcó C, Lóez Gonzóez PA, Lóez Cubillana P et al. [Morbidity and risk factors of transrectal prostate biopsy]. Actas Urol. Esp. 34(6), 531-536 (2010
22. Pinkhasov GI, Lin YK, Palmerola R et al. Complications following prostate needle biopsy requiring hospital admission or emergency department visits -experience from 1000 consecutive cases. BJU Int. 110(3), 369-374 (2012
23. Nam RK, Saskin R, Lee Y et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J. Urol. 183(3), 963-968 (2010
24. Wagenlehner FM, van Till JW, Magri V et al. National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) Symptom Evaluation in Multinational Cohorts of Patients with Chronic Prostatitis/Chronic Pelvic Pain Syndrome. Eur. Urol. 63(5), 953-959 (2013
25. Loeb S, Van Den Heuvel S, Zhu X, Bangma CH, Schr̈er FH, Roobol MJ. Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur. Urol. 61(6), 1110-1114 (2012
26. Clavien PA, Sanabria JR, Strasberg SM. Proposed classification of complications of surgery with examples of utility in cholecystectomy. Surgery 111(5), 518-526 (1992
27. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann. Surg. 240(2), 205-213 (2004
28. Zuazu JR, Hruza M, Rassweiler JJ, De La Rosette JJ. The Clavien classification system to optimize the documentation of PCNL morbidity. Arch. Ital. Urol. Androl. 82(1), 20-22 (2010
29. Heidenreich A, Aus G, Bolla M et al.; European Association of Urology. EAU guidelines on prostate cancer. Actas Urol. Esp. 33(2), 113-126 (2009
30. Carlsson SV, Holmberg E, Moss SM et al. No excess mortality after prostate biopsy: Results from the European Randomized Study of Screening for Prostate Cancer. BJU Int. 107(12), 1912-1917 (2011
31. Masood J, Hafeez A, Calleary J, Barua JM. Aspirin use and transrectal ultrasonography-guided prostate biopsy: A national survey. BJU Int. 99(5), 965-966 (2007
32. Burger W, Chemnitius JM, Kneissl GD, Rüker G. Low-Dose aspirin for secondary cardiovascular prevention -cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation -review and meta-Analysis. J. Intern. Med. 257(5), 399-414 (2005
33. Giannarini G, Mogorovich A, Valent F et al. Continuing or discontinuing low-Dose aspirin before transrectal prostate biopsy: Results of a prospective randomized trial. Urology 70(3), 501-505 (2007
34. Herget EJ, Saliken JC, Donnelly BJ, Gray RR, Wiseman D, Brunet G. Transrectal ultrasound-guided biopsy of the prostate: Relation between ASA use and bleeding complications. Can. Assoc. Radiol. J. 50(3), 173-176 (1999
35. Carmignani L, Picozzi S, Bozzini G et al. Transrectal ultrasound-guided prostate biopsies in patients taking aspirin for cardiovascular disease: A meta-Analysis. Transfus. Apher. Sci. 45(3), 275-280 (2011
36. Berger AP, Gozzi C, Steiner H et al. Complication rate of transrectal ultrasound guided prostate biopsy: A comparison among 3 protocols with 6, 10 and 15 cores. J. Urol. 171(4), 1478-1480; discussion 1480 (2004
37. Tüfek I, Akpinar H, Atug F et al. The impact of local anesthetic volume and concentration on pain during prostate biopsy: A prospective randomized trial. J. Endourol. 26(2), 174-177 (2012
38. Collins GN, Lloyd SN, Hehir M, McKelvie GB. Multiple transrectal ultrasound-guided prostatic biopsies -True morbidity and patient acceptance. Br. J. Urol. 71(4), 460-463 (1993
39. Irani J, Fournier F, Bon D, Gremmo E, Doré B, Aubert J. Patient tolerance of transrectal ultrasound-guided biopsy of the prostate. Br. J. Urol. 79(4), 608-610 (1997
40. Tiong HY, Liew LC, Samuel M, Consigliere D, Esuvaranathan K. A meta-Analysis of local anesthesia for transrectal ultrasound-guided biopsy of the prostate. Prostate Cancer Prostatic Dis. 10(2), 127-136 (2007
41. Walker AE, Schelvan C, Rockall AG, Rickards D, Kellett MJ Does pericapsular lignocaine reduce pain during transrectal ultrasonography-guided biopsy of the prostate? BJU Int. 90(9), 883-886 (2002
42. Lynn NN, Collins GN, Brown SC, OReilly PH. Periprostatic nerve block gives better analgesia for prostatic biopsy. BJU Int. 90(4), 424-426 (2002
43. Giannarini G, Autorino R, Valent F et al. Combination of perianal-intrarectal lidocaine-prilocaine cream and periprostatic nerve block for pain control during transrectal ultrasound guided prostate biopsy: A randomized, controlled trial. J. Urol. 181(2), 585-591; discussion 591 (2009
44. Scattoni V, Nava L, Roscigno M, Montorsi F, Rigatti P. Prostatic transrectal ultrasound (TRUS) guided biopsy schemes and TRUS prostatic lesion-guided biopsies. Eur. Urol. Supl. 1, 21-27 (2002
45. Kabay S, Sahin L, Yaylak F, Aydin T. Caudal block anaesthesia for transrectal biopsy of prostate in patients with anal rectal disorders. Central European J. Urol. 62(1), 15-20 (2009
46. Rietbergen JB, Kruger AE, Kranse R, Schr̈er FH. Complications of transrectal ultrasound-guided systematic sextant biopsies of the prostate: Evaluation of complication rates and risk factors within a population-based screening program. Urology 49(6), 875-880 (1997
47. Lindert KA, Kabalin JN, Terris MK. Bacteremia and bacteriuria after transrectal ultrasound guided prostate biopsy. J. Urol. 164(1), 76-80 (2000
48. Zegarra Montes LZ, Sanchez Mejia AA, Loza Munarriz CA, Gutierrez EC. Semen and urine culture in the diagnosis of chronic bacterial prostatitis. Int. Braz J Urol 34(1), 30-37, discussion 38 (2008
49. Gurbuz C, Canat L, Atis G, Caskurlu T. Reducing infectious complications after transrectal prostate needle biopsy using a disposable needle guide: Is it possible? Int. Braz J Urol 37(1), 79-84; discussion 85 (2011
50. Manecksha RP, Nason GJ, Cullen IM et al. Prospective study of antibiotic prophylaxis for prostate biopsy involving 1100 men. ScientificWorldJournal. 2012, 650858 (2012
51. Carignan A, Roussy JF, Lapointe V, Valiquette L, Sabbagh R, Pïn J. Increasing risk of infectious complications after transrectal ultrasound-guided prostate biopsies: Time to reassess antimicrobial prophylaxis? Eur. Urol. 62(3), 453-459 (2012
52. Aron M, Rajeev TP, Gupta NP. Antibiotic prophylaxis for transrectal needle biopsy of the prostate: A randomized controlled study. BJU Int. 85(6), 682-685 (2000
53. Batura D, Rao GG, Bo Nielsen P, Charlett A. Adding amikacin to fluoroquinolonebased antimicrobial prophylaxis reduces prostate biopsy infection rates. BJU Int. 107(5), 760-764 (2011
54. Mosharafa AA, Torky MH, El Said WM, Meshref A. Rising incidence of acute prostatitis following prostate biopsy: Fluoroquinolone resistance and exposure is a significant risk factor. Urology 78(3), 511-514 (2011
55. Feliciano J, Teper E, Ferrandino M et al The incidence of fluoroquinolone resistant infections after prostate biopsy -Are fluoroquinolones still effective prophylaxis? J. Urol. 179(3), 952-955; discussion 955 (2008
56. Glaser AP, Novakovic K, Helfand BT. The impact of prostate biopsy on urinary symptoms, erectile function, and anxiety. Curr. Urol. Rep. 13(6), 447-454 (2012
57. Saräglu T, Unsal A, Taskin F, Seviñk L, Karaman CZ. The impact of pre-procedural waiting period and anxiety level on pain perception in patients undergoing transrectal ultrasound-guided prostate biopsy. Diagn. Interv. Radiol. 18(2), 195-199 (2012
58. Tsivian M, Qi P, Kimura M et al. The effect of noise-cancelling headphones or music on pain perception and anxiety in men undergoing transrectal prostate biopsy. Urology 79(1), 32-36 (2012
59. Kirby R, Fitzpatrick JM. Optimising repeat prostate biopsy decisions and procedures. BJU Int. 109(12), 1750-1754 (2012
60. Gallina A, Suardi N, Montorsi F et al. Mortality at 120 days after prostatic biopsy: A population-based study of 22,175 men. Int. J. Cancer 123(3), 647-652 (2008
61. Fiard G, Descotes JL, Rambeaud JJ, Hohn N, Troccaz J, Long JA. MRI-guided targeted prostate biopsies in the diagnosis of prostate cancer: A systematic literature review. Prog. Urol. 22(15), 903-912 (2012
62. Roethke M, Anastasiadis AG, Lichy M et al. MRI-guided prostate biopsy detects clinically significant cancer: Analysis of a cohort of 100 patients after previous negative TRUS biopsy. World J. Urol. 30(2), 213-218 (2012
63. Haffner J, Lemaitre L, Puech P et al. Role of magnetic resonance imaging before initial biopsy: Comparison of magnetic resonance imaging-Targeted and systematic biopsy for significant prostate cancer detection. BJU Int. 108(8 Pt 2), E171-E178 (2011
64. Fütterer JJ, Barentsz JO. MRI-guided and robotic-Assisted prostate biopsy. Curr. Opin. Urol. 22(4), 316-319 (2012
65. Wright GL Jr. SELDI proteinchip MS: A platform for biomarker discovery and cancer diagnosis. Expert Rev. Mol. Diagn. 2(6), 549-563 (2002
66. Wellmann A, Wollscheid V, Lu H et al. Analysis of microdissected prostate tissue with ProteinChip arrays-A way to new insights into carcinogenesis and to diagnostic tools. Int. J. Mol. Med. 9(4), 341-347 (2002
67. Bueno R, Loughlin KR, Powell MH, Gordon GJ. A diagnostic test for prostate cancer from gene expression profiling data. J. Urol. 171(2 Pt 1), 903-906 (2004
68. Porkka KP, Visakorpi T. Molecular mechanisms of prostate cancer. Eur. Urol. 45(6), 683-691 (2004